Effects of Tocilizumab (RoACTEMRA) on Biomarkers in Synovial Tissue of Patients with Rheumatoid Arthritis.

Trial Profile

Effects of Tocilizumab (RoACTEMRA) on Biomarkers in Synovial Tissue of Patients with Rheumatoid Arthritis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top